Enliven Therapeutics (ELVN) Non-Current Assets (2019 - 2026)
Enliven Therapeutics (ELVN) posted Non-Current Assets of $1.7 million for Q1 2026, up 32.95% sequentially from $1.3 million in Q4 2025, and down 79.22% YoY from $8.3 million in Q1 2025.
Enliven Therapeutics (ELVN) Non-Current Assets (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 79.22% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.5 million (down 41.44% YoY) and the FY2025 annual result came in at $1.3 million, down 83.1% from the prior year.
- Non-Current Assets climbed to $1.7 million in Q1 2026 per ELVN's latest filing, from $1.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $8.9 million in Q2 2024 and troughed at $410000.0 in Q2 2022.
- A 5-year average of $5.5 million and a median of $5.6 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 1199.02% in 2023, then slumped 83.1% in 2025.
- Over 5 years, Non-Current Assets stood at $5.5 million in 2022, then climbed by 3.08% to $5.7 million in 2023, then jumped by 33.54% to $7.6 million in 2024, then plunged by 83.1% to $1.3 million in 2025, then jumped by 32.95% to $1.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.7 million, $1.3 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.88 Mn |
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 8.27 Mn |
| Mar 31, 2025 | 8.25 Mn |
| Dec 31, 2024 | 7.63 Mn |
| Sep 30, 2024 | 8.43 Mn |
| Jun 30, 2024 | 8.92 Mn |
| Mar 31, 2024 | 5.58 Mn |
| Dec 31, 2023 | 5.72 Mn |
| Sep 30, 2023 | 5.44 Mn |
| Jun 30, 2023 | 5.33 Mn |
| Mar 31, 2023 | 4.86 Mn |
| Dec 31, 2022 | 5.55 Mn |
| Jun 30, 2022 | 410,000.00 |
| Mar 31, 2022 | 3.07 Mn |
| Dec 31, 2021 | 950,000.00 |
| Sep 30, 2021 | 1.03 Mn |
| Jun 30, 2021 | 1.11 Mn |